• info@reportsandmarkets.com
  • +44-020-3286-9338 (UK) | +1-214-736-7666 (US) | +1-740-994-0111 (US)
  • Sign In
  • Register

Pharmaceuticals & HealthcareFrontier Pharma: Orphan and Rare Dermatological Diseases - First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa

  • RnM2474174
  • |
  • 11 September, 2018
  • |
  • Global
  • |
  • 86 pages
  • |
  • GBI Research
  • |
  • Pharmaceuticals & Healthcare

Frontier Pharma: Orphan and Rare Dermatological Diseases - First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa

Summary

Orphan and rare dermatological diseases are considerably diverse in terms of pathophysiology, clinical presentation and disease severity. Many of these conditions are extremely debilitating and can even be life-threatening in some cases.

Disease visibility can also have a profoundly negative impact on patient confidence. Unmet need within the orphan and rare dermatology market is extremely high with some diseases having no effective treatments. The market is highly genericized and dominated to a large extent by products acting on hormones and their receptors.

Most of these are corticosteroids and are used for symptom management with no disease-modifying effects. There is a significant unmet need for more efficacious disease-modifying treatments and safer treatment options across orphan and rare dermatological diseases, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles as issues associated with the long-term use of available treatments.

This report covers all orphan and rare dermatology disorders, but there is a particular focus on six key indications, systemic sclerosis (scleroderma), alopecia, epidermolysis bullosa (EB), pemphigus vulgaris, vitiligo and cutaneous lupus erythematosus (CLE), as these conditions have the largest pipelines within the therapy area.

Scope

- There is a strong need for innovative new therapies across the orphan and rare dermatology market. How are orphan and rare dermatological diseases currently managed? What are the greatest unmet needs within this market?
- There are 262 pipeline products in development across all orphan and rare dermatological diseases. How does the composition of the pipeline compare with that of the existing market? Which molecular targets are most frequently acted upon by pipeline drugs? How do products in development for the key indications differ in terms of molecule type?
- Over one-third of pipeline products with a disclosed molecular target are first-in-class. How does the proportion of first-in-class products in development differ in terms of stage of development, molecule type and molecular target class? Which are the most promising first-in-class targets?
- The deals landscape has become more active in recent years. Which indications and products have attracted the highest deal values?

Reasons to buy

This report will allow you to:
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
- Visualize the composition of the market in terms of dominant molecule types and molecular targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class molecular targets. Using a proprietary matrix, first-in-class targets have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.


1 Table of Contents
1 Table of Contents 2
    1.1 List of Tables 4
    1.2 List of Figures 4
2 Executive Summary 6
    2.1 Neglected Therapy Area with High Levels of Genericization 6
    2.2 Diverse Pipeline Demonstrates Potential to Address Unmet Needs 6
    2.3 Increase in Strategic Consolidations in Recent Years 6
3 The Case for Innovation 7
    3.1 Growing Opportunities for Biologic Products 8
    3.2 Diversification of Molecular Targets 8
    3.3 Innovative First-in-Class Product Developments Remain Attractive 8
    3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation 9
    3.5 Sustained Innovation in Orphan and Rare Dermatological Diseases 9
    3.6 GBI Research Report Guidance 9
4 Clinical and Commercial Landscape 11
    4.1 Overview of the Dermatology Market 11
    4.2 Overview of Orphan and Rare Diseases 11
      4.2.1 Overview of Systemic Sclerosis (Scleroderma) 12
      4.2.2 Overview of Alopecia 12
      4.2.3 Overview of Epidermolysis Bullosa 12
      4.2.4 Overview of Pemphigus Vulgaris 13
      4.2.5 Overview of Vitiligo 13
      4.2.6 Overview of Cutaneous Lupus Erythematosus 13
    4.3 Symptoms 13
      4.3.1 Systemic sclerosis 13
      4.3.2 Alopecia 14
      4.3.3 Epidermolysis bullosa 14
      4.3.4 Pemphigus Vulgaris 14
      4.3.5 Vitiligo 14
      4.3.6 Cutaneous Lupus Erythematosus 14
    4.4 Diagnosis 14
      4.4.1 Systemic sclerosis 15
      4.4.2 Alopecia 15
      4.4.3 Epidermolysis bullosa 16
      4.4.4 Pemphigus Vulgaris 16
      4.4.5 Vitiligo 16
      4.4.6 Cutaneous Lupus Erythematosus 16
    4.5 Etiology 16
      4.5.1 Systemic Sclerosis 16
      4.5.2 Alopecia 16
      4.5.3 Epidermolysis Bullosa 17
      4.5.4 Pemphigus Vulgaris 17
      4.5.5 Vitiligo 17
      4.5.6 Cutaneous Lupus Erythematosus 18
    4.6 Pathophysiology 18
      4.6.1 Systemic Sclerosis 19
      4.6.2 Alopecia 19
      4.6.3 Epidermolysis Bullosa 19
      4.6.4 Pemphigus Vulgaris 19
      4.6.5 Vitiligo 19
      4.6.6 Cutaneous Lupus Erythematosus 20
    4.7 Epidemiology 20
      4.7.1 Systemic sclerosis 20
      4.7.2 Alopecia 20
      4.7.3 Epidermolysis Bullosa 21
      4.7.4 Pemphigus Vulgaris 21
      4.7.5 Vitiligo 21
      4.7.6 Cutaneous Lupus Erythematosus 21
    4.8 Co-morbidities and Complications 21
      4.8.1 Systemic Sclerosis 22
      4.8.2 Alopecia 22
      4.8.3 Epidermolysis Bullosa 22
      4.8.4 Pemphigus Vulgaris 22
      4.8.5 Vitiligo 22
      4.8.6 Cutaneous Lupus Erythematosus 22
    4.9 Treatment 22
      4.9.1 Systemic Sclerosis 23
      4.9.2 Alopecia 24
      4.9.3 Epidermolysis Bullosa 24
      4.9.4 Pemphigus Vulgaris 24
      4.9.5 Vitiligo 25
      4.9.6 Cutaneous Lupus Erythematosus 25
    4.10 Overview of Marketed Products 25
5 Assessment of Pipeline Product Innovation 27
    5.1 Overview 27
    5.2 Pipeline by Stage of Development and Molecule Type 27
      5.2.1 Overall Pipeline 27
      5.2.2 Pipeline by Key Indications 28
    5.3 Pipeline by Molecular Target 32
      5.3.1 Overall Pipeline 32
      5.3.2 Pipeline for Key Indications 33
    5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 35
    5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class 35
    5.6 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Stage of Development, Molecule Type and Molecular Target Class 37
    5.7 Ratio of First-in-Class Programs to First-in-Class Molecular Targets by Stage of Development, Molecule Type and Molecular Target Class 38
    5.8 List of All Pipeline Programs 40
6 Signaling Network, Disease Causation and Innovation Alignment 47
    6.1 Complexity of Signaling Networks in Orphan and Rare Dermatological Diseases 47
    6.2 Signaling Pathways and First-in-Class Molecular Target Integration 47
    6.3 First-in-Class Molecular Target Matrix Assessment 47
7 First-in-Class Molecular Target Evaluation 52
    7.1 Pipeline Programs Targeting Collagen type XVII (COL17A1) 52
    7.2 Pipeline Programs Targeting Collagen type VII, alpha 1 (COL7A1) 52
    7.3 Pipeline Programs Targeting Interleukin 2 Receptor Subunit Beta (IL2RB) 54
    7.4 Pipeline Programs Targeting Desmoglein 1 (DSG1) 55
    7.5 Pipeline Programs Targeting Nacht LRR and PYD Domains Containing Protein 3 (NLRP3) 56
    7.6 Pipeline Programs Targeting Interleukin 3 Receptor Subunit Alpha (IL3RA) 58
    7.7 Pipeline Programs Targeting Non-Receptor Tyrosine Protein Kinase TYK2 (TYK2) 59
    7.8 Pipeline Programs Targeting Interleukin 6 Receptor Subunit Beta (IL6ST) 61
    7.9 Pipeline Programs Targeting Potassium Voltage-Gated Channel Subfamily A Member 3 (KCNA3) 62
    7.10 Pipeline Programs Targeting Kallikrein 7 (KLK7) 63
    7.11 Pipeline Programs Targeting Eotaxin (CCL11) 64
    7.12 Pipeline Programs Targeting Interleukin 2 (IL2) 65
8 Strategic Consolidations 67
    8.1 Industry-wide First-in-Class Deals 67
    8.2 Licensing Deals 68
      8.2.1 Deals by Region, Value and Year 68
      8.2.2 Deals by Key Indication and Value 69
      8.2.3 Deals by Stage of Development and Value 70
      8.2.4 Deals by Molecule Type and Molecular Target 71
      8.2.5 List of Deals with Disclosed Deal Values 72
    8.3 Co-development Deals 73
      8.3.1 Deals by Region, Value and Year 73
      8.3.2 Deals by Indication and Value 74
      8.3.3 Deals by Stage of Development and Value 74
      8.3.4 Deals by Molecule Type and Molecular Target 74
      8.3.5 List of Deals with Disclosed Deal Values 76
    8.4 First-in-Class Programs with and without Prior Licensing or Co-development Deal Involvement 76
9 Appendix 79
    9.1 References 79
    9.2 Abbreviations 83
    9.3 Pipeline Disease List 84
    9.4 Methodology 84
      9.4.1 Data Integrity 84
      9.4.2 Innovative and Meaningful Analytical Techniques and Frameworks 85
      9.4.3 Evidence Based Analysis and Insight 85
    9.5 Secondary Research 85
      9.5.1 Market Analysis 85
      9.5.2 Pipeline Analysis 85
      9.5.3 Licensing and Co-development Deals 86
    9.6 Contact Us 86
    9.7 Disclaimer 86


captcha
Enter the code in the box:


captcha
Enter the code in the box:

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.


captcha
Enter the code in the box:



Summary:
Get latest Market Research Reports on Frontier Pharma: Orphan and Rare Dermatological Diseases. Industry analysis & Market Report on Frontier Pharma: Orphan and Rare Dermatological Diseases is a syndicated market report, published as Frontier Pharma: Orphan and Rare Dermatological Diseases - First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa. It is complete Research Study and Industry Analysis of Frontier Pharma: Orphan and Rare Dermatological Diseases market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$6,995.00
$13,990.00
$20,985.00
4,697.14
9,394.29
14,091.43
6,436.80
12,873.60
19,310.40
847,374.30
1,694,748.60
2,542,122.90
463,862.23
927,724.47
1,391,586.70
Add To Cart Credit card Logo

Related Reports


Reason to Buy